Targeting hepatocyte-derived factors to improve the efficacy of immunotherapy in pancreatic cancer

The Trustees of the University of Pennsylvania were awarded a $560,870 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from September 2021 through September 2024 to target hepatocyte-derived factors in order to improve the efficacy of immunotherapy for pancreatic cancer.

The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield needs. This Project Grant aims to advance those objectives by exploring how hepatocyte-derived factors impact immunotherapy response for pancreatic cancer over a three year period, with the potential to lead to more effective treatment options for Service Members and the general public.